Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 13Breast 6Head & Neck 5Gastrointestinal 5Gynecologic 3Dermatologic 3Thoracic 2Sarcoma 2Lymphoid 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1CNS 1

Conditions

Sarcoma 8Melanoma 3Hemangiosarcoma 3Breast Neoplasms 3Prostatic Neoplasms 2Osteosarcoma 2Neoplasms 2Leiomyosarcoma 2Carcinosarcoma 2Carcinoma, Endometrioid 2Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liposarcoma 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Hemangioendothelioma, Epithelioid 1

Interventions

Gemcitabine 4pembrolizumab 3Docetaxel 3Cryosurgery 3Biopsy 3eribulin 2durvalumab 2balstilimab 2atezolizumab 2aflibercept 2Zoledronic Acid 2Trastuzumab 2Taxes 2Specimen Handling 2Radiotherapy 2Radiosurgery 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Letrozole 2Irinotecan 2Gene Expression Profiling 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 2Bevacizumab 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × durvalumab × Sarcoma × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡